Sunesis Pharmaceuticals (SNSS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sunesis Pharmaceuticals (SNSS)

SNSS 5.320

+24.3%

Feb 24 3:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (9)	11/17/2005 9:37:25 PM
From: tnsaf	of 48

<<The abstract says the G2 phase, the PR says the S phase>> Maybe you've seen this: from the following link, it acts in S and suspends in G2. Not clear what happens to the suspended cells. shareholder.com Sunesis Presents Data on Anti-Cancer Therapy, SNS-595 at American Association of Cancer Research Meeting [...] SNS-595, a novel cell-cycle inhibitor in Phase I clinical trials, causes tumor regressions, cell cycle arrest, and apoptosis in murine models of colon cancer Abstract # 2277 The Phase I clinical compound SNS-595 acts during S-phase and causes sustained G2 arrest Abstract # 2293 The potent cytotoxic agent SNS-595 causes a rapid onset of apoptosis during the S-phase of the cell cycle Abstract # 2285

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next